Opinion

Video

Quadruplet Induction Regimen in Newly Diagnosed Multiple Myeloma

Panelists discuss whether daratumumab quadruplet induction regimens should be considered the new standard of care for newly diagnosed transplant-eligible patients and explore scenarios in which a triplet induction regimen might still be appropriate. They also review the findings from the ISKIA and GMMG-CONCEPT trials, including considerations for using isatuximab-carfilzomib (IsaKRd) over D-VRd.

  1. In your clinical opinion, are daratumumab quadruplet induction regimens the new standard of care for newly diagnosed (transplant-eligible) patients? Are there patients for whom you would still consider a triplet induction regimen?
  2. Could you also review the ISKIA & GMMG-CONCEPT trials and findings? Are there any clinical scenarios where you would consider an isatuximab-carfilzomib (IsaKRd) quadruplet over D-VRd?
Related Videos
Related Content